UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2022.

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 001-16537

ORASURE TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Its Charter)



Delaware		36-4370966
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)



220 East First Street, Bethlehem, Pennsylvania		18015
(Address of Principal Executive Offices)		(Zip code)

Registrant’s telephone number, including area code: (610) 882-1820

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value per share

OSUR

The NASDAQ Stock Market LLC

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☐

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 5,~~November 3, 2022, the registrant had ~~72,619,055~~72,622,043 shares of common stock, ~~$.000001~~$0.000001 par value per share, outstanding.

PART I. FINANCIAL INFORMATION



	Page No.

Item 1. Financial Statements (Unaudited)

Consolidated Balance Sheets at ~~June~~September 30, 2022 and December 31, 2021	3

Consolidated Statements of Operations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021	4

Consolidated Statements of Comprehensive ~~Income (Loss)~~Loss for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021	5

Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021	6

Notes to the Consolidated Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3. Quantitative and Qualitative Disclosures About Market Risk	31

Item 4. Controls and Procedures	31

PART II. OTHER INFORMATION

Item 1. Legal Proceedings	3132

Item 1A. Risk Factors	3132

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	32

Item 3. Defaults Upon Senior Securities	32

Item 4. Mine Safety Disclosures	32

Item 5. Other Information	3233

Item 6. Exhibits	33

Signatures	34

Item 1. FINANCIAL STATEMENTS

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except per share amounts)


	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
ASSETS
Current Assets:
Cash and cash equivalents	$	66,159		$	116,762		$	75,205		$	116,762
Short-term investments		29,625			36,279			26,432			36,279
Accounts receivable, net of allowance for doubtful accounts of $3,222 and $3,418		62,886			45,323
Accounts receivable, net of allowance for doubtful accounts of $4,176 and $3,418								61,306			45,323
Inventories		71,304			53,138			78,805			53,138
Prepaid expenses		5,477			7,939			5,844			7,939
Other current assets		31,855			28,990			32,140			28,990
Total current assets		267,306			288,431			279,732			288,431
Noncurrent Assets:
Property, plant and equipment, net		93,697			88,164			85,184			88,164
Operating right-of-use assets, net		16,451			9,056			15,769			9,056
Finance right-of-use assets, net		1,887			2,493			1,590			2,493
Intangible assets, net		12,851			14,343			11,919			14,343
Goodwill		36,038			40,279			34,476			40,279
Long-term investments		—			17,009			—			17,009
Other noncurrent assets		1,024			1,215			3,538			1,215
Total noncurrent assets		161,948			172,559			152,476			172,559
TOTAL ASSETS	$	429,254		$	460,990		$	432,208		$	460,990
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	36,226		$	28,024		$	40,370		$	28,024
Deferred revenue		2,660			2,936			2,536			2,936
Accrued expenses and other current liabilities		23,165			33,778			25,412			33,778
Finance lease liabilities		1,182			939			1,242			939
Operating lease liabilities		2,054			2,181			1,938			2,181
Acquisition-related contingent consideration obligation		199			206			199			206
Total current liabilities		65,486			68,064			71,697			68,064
Noncurrent Liabilities:
Finance lease liabilities		1,445			1,952			935			1,952
Operating lease liabilities		14,978			7,202			14,493			7,202
Acquisition-related contingent consideration obligation		117			354			117			354
Other noncurrent liabilities		489			651			525			651
Deferred income taxes		2,547			2,234			2,551			2,234
Total noncurrent liabilities		19,576			12,393			18,621			12,393
TOTAL LIABILITIES		85,062			80,457			90,318			80,457
Commitments and contingencies (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, NaN issued		—			—
Common stock, par value $.000001, 120,000 shares authorized, 72,572 and 72,069 shares issued and outstanding		0			0
Preferred stock, par value $.000001, 25,000 shares authorized, none issued								—			—
Common stock, par value $.000001, 120,000 shares authorized, 72,619 and 72,069 shares issued and outstanding								—			—
Additional paid-in capital		515,928			511,063			518,170			511,063
Accumulated other comprehensive loss		(12,514	)		(10,077	)		(22,331	)		(10,077	)
Accumulated deficit		(159,222	)		(120,453	)		(153,949	)		(120,453	)
Total stockholders' equity		344,192			380,533			341,890			380,533
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	429,254		$	460,990		$	432,208		$	460,990

See accompanying notes to the consolidated financial statements.

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share amounts)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
NET REVENUES:
Products and services	$	79,167		$	55,741		$	144,403		$	112,320		$	112,821		$	53,229		$	257,224		$	165,549
Other		1,064			1,866			3,535			3,869			3,642			688			7,177			4,557
		80,231			57,607			147,938			116,189			116,463			53,917			264,401			170,106
COST OF PRODUCTS AND SERVICES SOLD		52,647			26,934			96,082			47,190			70,271			32,449			166,353			79,639
Gross profit		27,584			30,673			51,856			68,999			46,192			21,468			98,048			90,467
OPERATING EXPENSES:
Research and development		9,068			7,682			17,481			16,674			9,757			8,596			27,238			25,270
Sales and marketing		11,684			10,420			24,401			19,950			13,474			13,886			37,875			33,836
General and administrative		17,579			10,993			36,735			21,181			15,527			12,499			52,262			33,680
Loss on impairment		10,542			—			10,542			—			6,559			—			17,101			—
Change in the estimated fair value of acquisition-related contingent consideration		—			(220	)		(36	)		(1,026	)		—			(500	)		(36	)		(1,526	)
		48,873			28,875			89,123			56,779			45,317			34,481			134,440			91,260
Operating income (loss)		(21,289	)		1,798			(37,267	)		12,220			875			(13,013	)		(36,392	)		(793	)
OTHER INCOME		1,318			448			1,265			329			3,255			100			4,520			429
Income (loss) before income taxes		(19,971	)		2,246			(36,002	)		12,549			4,130			(12,913	)		(31,872	)		(364	)
INCOME TAX EXPENSE (BENEFIT)		(1,169	)		3,610			2,767			10,139			(1,143	)		2,102			1,624			12,241
NET INCOME (LOSS)	$	(18,802	)	$	(1,364	)	$	(38,769	)	$	2,410		$	5,273		$	(15,015	)	$	(33,496	)	$	(12,605	)
INCOME (LOSS) PER SHARE:
BASIC	$	(0.26	)	$	(0.02	)	$	(0.54	)	$	0.03		$	0.07		$	(0.21	)	$	(0.46	)	$	(0.18	)
DILUTED	$	(0.26	)	$	(0.02	)	$	(0.54	)	$	0.03		$	0.07		$	(0.21	)	$	(0.46	)	$	(0.18	)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC		72,496			71,983			72,361			71,931			72,616			72,023			72,448			71,962
DILUTED		72,496			71,983			72,361			72,683			72,785			72,023			72,448			71,962

See accompanying notes to the consolidated financial statements.

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE ~~INCOME (LOSS)~~LOSS

(Unaudited)

(in thousands)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
NET INCOME (LOSS)	$	(18,802	)	$	(1,364	)	$	(38,769	)	$	2,410		$	5,273		$	(15,015	)	$	(33,496	)	$	(12,605	)
OTHER COMPREHENSIVE INCOME (LOSS)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments		(4,349	)		1,403			(2,593	)		2,755			(9,828	)		(4,117	)		(12,421	)		(1,362	)
Unrealized gain (loss) on marketable securities		82			(122	)		156			(101	)		11			(161	)		167			(262	)
COMPREHENSIVE INCOME (LOSS)	$	(23,069	)	$	(83	)	$	(41,206	)	$	5,064
COMPREHENSIVE LOSS													$	(4,544	)	$	(19,293	)	$	(45,750	)	$	(14,229	)

See accompanying notes to the consolidated financial statements.

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Six Months Ended June 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
OPERATING ACTIVITIES:
Net income (loss)	$	(38,769	)	$	2,410		$	(33,496	)	$	(12,605	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation		6,804			2,937			9,100			5,155
Depreciation and amortization		7,464			5,144			11,391			8,479
Loss on impairment		10,542			—			17,101			—
Other non-cash amortization		313			380			411			664
Provision for doubtful accounts		(152	)		747			974			1,228
Inventory reserve		1,989			1,168			977			2,908
Unrealized foreign currency gain		(62	)		(364	)		(396	)		(319	)
Interest expense on finance leases		55			35			74			84
Deferred income taxes		361			(218	)		542			(324	)
Loss on disposal of fixed assets		718			—			729			—
Change in the estimated fair value of acquisition-related contingent consideration		(36	)		(1,026	)		(36	)		(1,526	)
Payment of acquisition-related contingent consideration		—			(142	)		—			(142	)
Changes in assets and liabilities
Accounts receivable		(18,646	)		3,680			(19,152	)		(2,102	)
Inventories		(20,385	)		(17,233	)		(27,586	)		(24,597	)
Prepaid expenses and other assets		(4,416	)		154			(5,990	)		(1,942	)
Accounts payable		11,942			4,400			16,246			2,790
Deferred revenue		(252	)		(630	)		(312	)		(1,331	)
Accrued expenses and other liabilities		(2,959	)		(4,914	)		233			982
Net cash used in operating activities		(45,489	)		(3,472	)		(29,190	)		(22,598	)
INVESTING ACTIVITIES:
Purchases of investments		—			(10,428	)		(22,873	)		(25,443	)
Proceeds from maturities and redemptions of investments		23,017			43,745			47,415			53,745
Purchases of property and equipment		(25,440	)		(22,929	)		(28,081	)		(27,508	)
Purchase of property and equipment under government contracts		(33,803	)		—			(38,705	)		—
Proceeds from funding under government contract		33,962			—			37,756			—
Other investing activities		—			(18	)		—			(18	)
Net cash (used in) provided by investing activities		(2,264	)		10,370			(4,488	)		776
FINANCING ACTIVITIES:
Cash payments for lease liabilities		(392	)		(510	)		(826	)		(1,111	)
Proceeds from exercise of stock options		15			121			15			247
Payment of acquisition-related contingent consideration		(208	)		(264	)		(208	)		(264	)
Repurchase of common stock		(1,954	)		(1,877	)		(2,008	)		(1,924	)
Net cash used in financing activities		(2,539	)		(2,530	)		(3,027	)		(3,052	)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		(311	)		(7,050	)		(4,852	)		(966	)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(50,603	)		(2,682	)		(41,557	)		(25,840	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		116,762			160,802			116,762			160,802
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	66,159		$	158,120		$	75,205		$	134,962

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	$	9,107		$	10,329		$	9,400		$	12,540
Non-cash investing and financing activities
Accrued property and equipment purchases		1,900			896			1,463			4,382
Accrued property and equipment purchases under government contracts		2,023			—			2,374			—
Unrealized gain (loss) on marketable securities		156			(101	)		167			(262	)

See accompanying notes to the consolidated financial statements.

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(Unaudited)

(in thousands, except per share amounts, unless otherwise indicated)

1. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 are not necessarily indicative of the results of operations expected for the full year.

Summary of Significant Accounting Policies. There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds purchased with maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. During the ~~six~~nine months ended ~~June~~September 30, 2022, we recognized a provision for expected credit losses for our available-for-sale securities of $7256.

The following is a summary of our available-for-sale securities as of ~~June~~September 30, 2022 and December 31, 2021:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2022
September 30, 2022
Guaranteed investment certificates	$	24,860	$	—	$	—		$	24,860	$	21,688	$	—	$	—		$	21,688
Corporate bonds		5,043		—		(278	)		4,765		5,011		—		(267	)		4,744
Total available-for-sale securities	$	29,903	$	—	$	(278	)	$	29,625	$	26,699	$	—	$	(267	)	$	26,432
December 31, 2021
Guaranteed investment certificates	$	33,249	$	—	$	—		$	33,249	$	33,249	$	—	$	—		$	33,249
Corporate bonds		20,473		—		(434	)		20,039		20,473		—		(434	)		20,039
Total available-for-sale securities	$	53,722	$	—	$	(434	)	$	53,288	$	53,722	$	—	$	(434	)	$	53,288
At June 30, 2022, maturities of our available-for-sale securities were as follows:
At September 30, 2022, maturities of our available-for-sale securities were as follows:
Less than one year	$	29,903	$	—	$	(278	)	$	29,625	$	26,699	$	—	$	(267	)	$	26,432
Greater than one year	$	—	$	—	$	—		$	—	$	—	$	—	$	—		$	—

Fair Value of Financial Instruments. As of ~~June~~September 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of ~~June~~September 30, 2022 and December 31, 2021. Our available-for-sale guaranteed investment certificates are measured as Level 1 instruments as of ~~June~~September 30, 2022 and December 31, 2021.

Included in cash and cash equivalents at ~~June~~September 30, 2022 and December 31, 2021, was $~~5,636~~1,717 and $1,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of ~~June~~September 30, 2022 and December 31, 2021 was $~~1,576~~1,599 and $1,763, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of ~~June~~September 30, 2022 and December 31, 2021 was $~~66,468~~68,626 and $61,157, respectively.

Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of ~~June~~September 30, 2022 and December 31, 2021 was $~~30,988~~29,943 and $30,412, respectively. The decrease in intangible assets from $14,343 as of December 31, 2021 to $~~12,851~~11,919 as of ~~June~~September 30, 2022 was due to $~~1,120~~1,617 in amortization expense and foreign currency translation losses of $~~372~~807.

Impairment of Long-Lived Assets. Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time.

During the three months ended ~~June~~September 30, 2022, management ~~decided to move three idle~~determined several manufacturing ~~cells to storage~~lines and associated supporting assets will not be utilized due to changes in forecasted demand for the products the ~~cells~~lines are intended to produce. As a result of this decision, we determined that the carrying values of the equipment is not recoverable and recorded an aggregate pre-tax asset impairment charge of $~~6,938~~6,559 during the three months ended ~~June~~September 30, 2022 to write the assets down to their estimated fair values. This charge is reported within loss on ~~impairments~~impairment in the consolidated statement of operations.

We estimated the fair value of the impaired long-lived assets using a market approach, which required us to estimate the value that would be received for the equipment in the ~~principal or~~ most advantageous market for that equipment in an orderly transaction between market participants. Due to the extremely specialized nature of the manufacturing equipment and various market data points, the estimated fair value was not significant. Our fair value estimates were representative of Level 3 measurements within the fair value hierarchy due to the significant level of estimation involved and the lack of transparency as to the inputs used.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains resulting from

foreign currency transactions that are included in other income ~~(loss)~~ in our consolidated statements of operations were $~~783~~2,342 and $~~198~~7 for the three months ended ~~June~~September 30, 2022 and 2021, respectively. Net foreign exchange gains (losses) were $542,396 and $(~~379~~371) for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at ~~June~~September 30, 2022 consisted of $~~12,236~~22,064 of currency translation adjustments and $~~278~~267 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2021 consists of $9,643 of currency translation adjustments and $434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio.

Recent Accounting Pronouncements.

In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued a proposed amendment to the ASU in April 2022 which, if approved, will extend the date for prospective application to December 31, 2024. Management has evaluated this ASU and concluded that it will not have a material impact on the Company's Consolidated Financial Statements.

2. Government Capital Contracts

In September 2021, we entered into an agreement for $109,000 in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for our InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. Funding will be paid to the Company based on achievement of milestones through March 2024 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15% of the total will not be funded until the completion of the final equipment validation, which is scheduled to occur in late 2023 or early 2024. We began making payments to vendors for the capital project during the fourth quarter of 2021 and began receiving funds from the DOD in January 2022.

Additionally, during 2021, we received $531 in funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for the purchase of machinery and equipment as part of an expansion of manufacturing operations in Pennsylvania. All related purchases were completed in 2021.

Activity for these capital contracts is accounted for pursuant to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding earned in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Amounts earned in excess of our expected cost of the project for project management are recognized straight-line in other income over the term of the government contract. We recognized $561 and $~~1,123~~1,684 of such income for the three and ~~six~~nine months ended ~~June~~September 30, 2022, respectively, which is reported as other income ~~(loss)~~ in our consolidated statement of operations.

The balances corresponding to government contracts included in our consolidated balance sheet are as follows:


	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Other current assets:
Billed receivables	$	—		$	9,913		$	1,489		$	9,913
Unbilled receivables		15,748			9,716			13,840			9,716
Total other current assets		15,748			19,629			15,329			19,629
Property, plant and equipment, net:
Cost of assets, cumulative		47,321			11,495			50,200			11,495
Reduction for funding earned to date, not yet received		(12,828	)		(10,964	)		(11,913	)		(10,964	)
Reduction for funding received to date		(34,493	)		(531	)		(38,287	)		(531	)
Total property, plant and equipment, net		—			0			—			—
Other non-current assets - unbilled receivables								2,489			—
Accrued expenses and other current liabilities		(620	)		(8,103	)	$	(404	)	$	(8,103	)

3. Inventories


	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Raw materials	$	37,292	$	33,168	$	37,137	$	33,168
Work in process		2,348		2,252		2,499		2,252
Finished goods		31,664		17,718		39,169		17,718
	$	71,304	$	53,138	$	78,805	$	53,138

4. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

The computations of basic and diluted earnings (loss) per share are as follows:


	Three Months Ended June 30,						Six Months Ended June 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2022			2021			2022			2021		2022		2021			2022			2021

Net income (loss)	$	(18,802	)	$	(1,364	)	$	(38,769	)	$	2,410	$	5,273	$	(15,015	)	$	(33,496	)	$	(12,605	)
Weighted-average shares of common stock outstanding:
Basic		72,496			71,983			72,361			71,931		72,616		72,023			72,448			71,962
Dilutive effect of stock options, restricted stock, and performance stock units		—			—			—			752		169		—			—			—
Diluted		72,496			71,983			72,361			72,683		72,785		72,023			72,448			71,962
Earnings (loss) per share:
Basic	$	(0.26	)	$	(0.02	)	$	(0.54	)	$	0.03	$	0.07	$	(0.21	)	$	(0.46	)	$	(0.18	)
Diluted	$	(0.26	)	$	(0.02	)	$	(0.54	)	$	0.03	$	0.07	$	(0.21	)	$	(0.46	)	$	(0.18	)

For the three months ended ~~June 30, 2022, three months ended June 30, 2021 and six months ended June 30, 2022,~~September 30,2022, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing ~~226~~, ~~603, and~~ ~~381~~ shares, respectively, were excluded from the computation of diluted loss per share. For the six months ended June 30, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing ~~604~~1,734 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2022, and the three and nine months ended September 30, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 383, 859, and 847 shares, respectively, were excluded from the computation of diluted loss per share.

5. Revenues

Revenues by product line. The following table represents total net revenues by product line:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
COVID-19 ~~(1)~~	$	43,378	$	12,070	$	74,411	$	40,215	$	79,920	$	13,930	$	154,331	$	54,147
Genomics ~~(1)~~		15,486		19,498		30,578		30,316		13,980		19,018		44,558		49,333
HIV		10,357		10,944		18,523		19,722		9,054		10,022		27,577		29,745
HCV		3,691		4,300		6,948		6,668		3,234		2,715		10,182		9,382
Substance abuse		2,630		2,629		5,191		4,591		2,595		2,674		7,786		7,265
Microbiome ~~(1)~~		1,832		2,447		3,822		4,198		1,761		1,693		5,583		5,888
Laboratory services		1,204		3,114		2,938		5,611		1,957		2,406		4,895		8,017
Other product and service revenues		589		739		1,992		999		320		771		2,312		1,772
Net product and services revenues		79,167		55,741		144,403		112,320		112,821		53,229		257,224		165,549
Royalty income		642		875		1,326		2,136		409		500		1,735		2,636
Other non-product revenues		422		991		2,209		1,733
Other non-product revenues*										3,233		188		5,442		1,921
Other revenues		1,064		1,866		3,535		3,869		3,642		688		7,177		4,557
Net revenues	$	80,231	$	57,607	$	147,938	$	116,189	$	116,463	$	53,917	$	264,401	$	170,106

~~(1)~~ ~~2021 COVID-19, Genomics~~*Other non-product revenues include funded research and Microbiome revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the three months ended June 30, 2021 by $~~490, $(~~84)development under our BARDA contracts and $(~~406), respectively. The reclassification increased (decreased) the product line revenues for the six months ended June 30, 2021 by $1,073, $(330) and $(743), respectively~~.other grant revenues.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
United States	$	70,320	$	47,601	$	128,307	$	96,700	$	108,941	$	42,969	$	237,248	$	139,669
Europe		2,436		3,325		6,722		7,877		2,207		2,411		8,929		10,288
Other regions		7,475		6,681		12,909		11,612		5,315		8,537		18,224		20,149
	$	80,231	$	57,607	$	147,938	$	116,189	$	116,463	$	53,917	$	264,401	$	170,106

Customer and Vendor Concentrations. At ~~June~~September 30, 2022, one non-commercial customer accounted for 48~~% of our accounts receivable and another commercial customer accounted for~~ 1047% of our accounts receivable. No customers accounted for more than 10% of our accounts receivable as of December 31, 2021. One non-commercial customer accounted for 5669% and 3953% of net consolidated revenues for the three and ~~six~~nine months ended ~~June~~September 30, ~~2022.~~2022, respectively. One customer accounted for 14% of net consolidated revenues for the three months ended ~~June~~September 30, 2021. Another customer accounted for 10% ~~and~~ 14~~%, respectively,~~ of net consolidated revenues for the ~~three and six~~nine months ended ~~June~~September 30, 2021.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of ~~June~~September 30, 2022 and December 31, 2021 includes customer prepayments of $~~1,746~~1,762 and $1,843, respectively. Deferred revenue as of ~~June~~September 30, 2022 and December 31, 2021 also includes $~~914~~774 and $1,093, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

6. Goodwill

The following table represents the changes in goodwill by operating segment for the ~~six~~nine months ended ~~June~~September 30, 2022:


	June 30, 2022
	Diagnostics			Molecular Solutions			Diagnostics			Molecular Solutions
Balance as of January 1	$	3,604		$	36,675
Balance as of January 1, 2022							$	3,604		$	36,675
Impairment		(3,604	)		—			(3,604	)		—
Change related to foreign currency translation		—			(637	)		—			(2,199	)
Balance as of June 30	$	—		$	36,038
Balance as of September 30, 2022							$	—		$	34,476

We perform an annual goodwill impairment assessment as of July 31 each year by comparing the estimated fair values of our reporting units to their respective carrying values. A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

During the ~~three months ended June 30,~~second quarter of 2022, we determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding significant decline in our market capitalization. As a result, we performed an interim goodwill impairment test and concluded that the carrying value of our Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. Thus, we recognized a pre-tax impairment charge of $3.6 million during the three months ended June 30, 2022, which is reported in loss on impairments in our condensed consolidated statement of operations.

WeIn the second quarter, we estimated fair values of both of our reporting units using a combined income-based approach and market-based approach. Our income approach utilized projected future cash flows that were discounted at a rate of 22% for the Diagnostic reporting unit and 20% for the Molecular Solutions reporting unit based on a weighted-average cost of capital analysis that reflected current market conditions. The market comparable approach primarily considered earnings, revenue and other multiples of comparable companies and applied those multiples to certain key drivers of the reporting units. This market approach utilized a revenue multiple weighted by year for the Diagnostics reporting unit and both a revenue and EBITDA multiple for the Molecular Solutions reporting unit. We assigned a weight of 75% to the results of our income-based approach and 25% to the results from the market-based approach for estimation of the reporting units' fair value. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.

We perform an annual goodwill impairment assessment as of July 31 each year. Historically this involved a qualitative analysis that resulted in a conclusion that it was more likely than not that the fair value of our reporting units is greater than their carrying value. In 2022, as a result of the depressed market price of the Company's common stock and corresponding significant decline in our market capitalization, we performed a quantitative analysis by comparing the estimated fair values of our reporting units to their respective carrying values. Our quantitative goodwill impairment test assessment as of July 31, 2022 concluded that the carrying value of our Molecular Solutions reporting unit exceeded its estimated fair value and no impairment of the related goodwill exists.

A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

7. Accrued Expenses and other current liabilities



	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Payroll and related benefits	$	11,636	$	15,570	$	11,263	$	15,570
Commitment to purchase under government contract		—		8,103		—		8,103
Deferred income for government contract		620		—
Professional fees		3,799		3,335		4,771		3,335
Sales tax payable		1,807		2,227		1,372		2,227
Other		5,303		4,543		8,006		4,543
	$	23,165	$	33,778	$	25,412	$	33,778

8. Leases

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of ~~June~~September 30, 2022, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 11 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Operating lease cost	$	811	$	499	$	1,510	$	919	$	842	$	655	$	2,352	$	1,574
Variable and short-term lease cost		152		—		227		—		332		—		559		—
Finance lease cost:
Amortization of right-of use assets		306		212		691		339		343		571		1,034		910
Interest on lease liabilities		23		21		55		35		19		49		74		84
Total finance lease cost		329		233		746		374		362		620		1,108		994
Total lease cost	$	1,292	$	732	$	2,483	$	1,293	$	1,536	$	1,275	$	4,019	$	2,568

Supplemental cash flow information related to leases is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,027	$	416	$	2,213	$	824	$	3,659	$	1,182
Operating cash flows from financing leases		23		21		55		35		74		84
Financing cash flows from financing leases		239		228		392		510		826		1,111
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		5,131		7,205		8,797		7,834		9,038		45
Right-of-use assets obtained in exchange for finance lease obligations		-		—		117		—		117		2,746

Supplemental balance sheet information related to leases is as follows:



	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Operating Leases
Right-of-use assets	$	16,451	$	9,056	$	15,769	$	9,056
Lease liabilities:
Current lease liabilities		2,054		2,181		1,938		2,181
Non-current lease liabilities		14,978		7,202		14,493		7,202
Total operating lease liabilities	$	17,032	$	9,383	$	16,431	$	9,383


Finance Leases
Right-of-use assets	$	1,887	$	2,493	$	1,590	$	2,493
Lease liabilities:
Current lease liabilities		1,182		939		1,242		939
Non-current lease liabilities		1,445		1,952		935		1,952
Total finance lease liabilities	$	2,627	$	2,891	$	2,177	$	2,891


Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	7.73 years			5.26 years			7.46 years			5.26 years
Weighted-average remaining lease term—finance leases	1.82 years			2.21 years			1.59 years			2.21 years

Weighted Average Discount Rate
Weighted-average discount rate—operating leases		4.27	%		3.90	%		4.25	%		3.90	%
Weighted-average discount rate—finance leases		3.52	%		3.57	%		3.45	%		3.57	%

As of ~~June~~September 30, 2022, minimum lease payments by period are expected to be as follows:

Finance

Operating

2022 (excluding the six months ended June 30, 2022)

$
710

$
1,496

2023

1,283

1,879

2024

740

2,969

2025

19

2,619

2026

11

2,422

Thereafter

—

9,021

Total minimum lease payments

2,763

20,406

Less: imputed interest

(136
)

(3,374
)
Present value of lease liabilities

$
2,627

$
17,032


	Finance			Operating
2022 (excluding the nine months ended September 30, 2022)	$	373		$	795
2023		1,125			2,043
2024		738			2,947
2025		18			2,583
2026		11			2,385
Thereafter		—			8,800
Total minimum lease payments		2,265			19,553
Less: imputed interest		(88	)		(3,122	)
Present value of lease liabilities	$	2,177		$	16,431

On October 19, 2022, the Company entered into a termination agreement for a warehouse entered into on January 3, 2022, related to its 96,010 square foot facility in York, Pennsylvania. Pursuant to the terms of the termination agreement, the lease terminated, effective on October 31, 2022. The Company is not required to pay a termination fee, and has been released from all further rent obligations under the lease, resulting in ongoing annual cash savings of approximately $735. Termination will result in an operating right-of-use assets and lease liabilities reduction of $4,927 and $5,146, respectively.

9. Stockholders’ Equity


Reconciliation of the changes in stockholders' equity for the three and six months ended June 30, 2022 and 2021
Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021																		Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated							Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total				Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2021		72,069		$	—	$	511,063		$	(10,077	)	$	(120,453	)	$	380,533				72,069		$	—	$	511,063		$	(10,077	)	$	(120,453	)	$	380,533

Common stock issued upon exercise of options		2			—		15			—			—			15				2			—		15			—			—			15
Vesting of restricted stock and performance stock units		352			—		—			—			—			—				352			—		—			—			—			—
Purchase and retirement of common shares		(116	)		—		(1,049	)		—			—			(1,049	)			(116	)		—		(1,049	)		—			—			(1,049	)
Stock-based compensation		—			—		3,524			—			—			3,524				—			—		3,524			—			—			3,524
Net loss		—			—		—			—			(19,967	)		(19,967	)			—			—		—			—			(19,967	)		(19,967	)
Currency translation adjustments		—			—		—			1,756			—			1,756				—			—		—			1,756			—			1,756
Unrealized gain on marketable securities		—			—		—			74			—			74				—			—		—			74			—			74
Balance at March 31, 2022		72,307		$	—	$	513,553		$	(8,247	)	$	(140,420	)	$	364,886				72,307		$	—	$	513,553		$	(8,247	)	$	(140,420	)	$	364,886
Common stock issued upon exercise of options																				—			—		—			—			—			—
Vesting of restricted stock and performance stock units		407			—		—			—			—			—				407			—		—			—			—			—
Purchase and retirement of common shares		(142	)		—		(905	)		—			—			(905	)			(142	)		—		(905	)		—			—			(905	)
Stock-based compensation		—			—		3,280			—			—			3,280				—			—		3,280			—			—			3,280
Net loss		—			—		—			—			(18,802	)		(18,802	)			—			—		—			—			(18,802	)		(18,802	)
Currency translation adjustments		—			—		—			(4,349	)		—			(4,349	)			—			—		—			(4,349	)		—			(4,349	)
Unrealized gain on marketable securities		—			—		—			82			—			82				—			—		—			82			—			82
Balance at June 30, 2022		72,572		$	—	$	515,928		$	(12,514	)	$	(159,222	)	$	344,192				72,572		$	—	$	515,928		$	(12,514	)	$	(159,222	)	$	344,192
Common stock issued upon exercise of options																				—			—		—			—			—			—
Vesting of restricted stock and performance stock units																				66			—		—			—			—			—
Purchase and retirement of common shares																				(19	)		—		(54	)		—			—			(54	)
Stock-based compensation																				—			—		2,296			—			—			2,296
Net income																				—			—		—			—			5,273			5,273
Currency translation adjustments																				—			—		—			(9,828	)		—			(9,828	)
Unrealized loss on marketable securities																				—			—		—			11			—			11
Balance at September 30, 2022																				72,619		$	—	$	518,170		$	(22,331	)	$	(153,949	)	$	341,890



	Common Stock						Additional Paid-in			Accumulated Other Comprehensive			Accumulated						Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares				Amount		Capital			Loss			Deficit			Total			Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2020		71,738			$	—	$	505,123		$	(9,097	)	$	(97,455	)	$	398,571			71,738		$	—	$	505,123		$	(9,097	)	$	(97,455	)	$	398,571
Common stock issued upon exercise of options		11				—		92			—			—			92			11			—		92			—			—			92
Vesting of restricted stock and performance stock units		318				—					—			—			—			318			—					—			—			—
Purchase and retirement of common shares		(111	)			—		(1,730	)		—			—			(1,730	)		(111	)		—		(1,730	)		—			—			(1,730	)
Stock-based compensation		—				—		1,464			—			—			1,464			—			—		1,464			—			—			1,464
Net income		—				—		—			—			3,774			3,774			—			—		—			—			3,774			3,774
Currency translation adjustments		—				—		—			1,352			—			1,352			—			—		—			1,352			—			1,352
Unrealized gain on marketable securities		—				—		—			21			—			21			—			—		—			21			—			21
Balance at March 31, 2021		71,956			$	—	$	504,949		$	(7,724	)	$	(93,681	)	$	403,544			71,956		$	—	$	504,949		$	(7,724	)	$	(93,681	)	$	403,544
Common stock issued upon exercise of options		3				—		29			—			—			29			3			—		29			—			—			29
Vesting of restricted stock and performance stock units		64				—		—			—			—			—			64			—		—			—			—			—
Purchase and retirement of common shares		(15	)			—		(147	)		—			—			(147	)		(15	)		—		(147	)		—			—			(147	)
Stock-based compensation		—				—		1,473			—			—			1,473			—			—		1,473			—			—			1,473
Net loss		—				—		—			—			(1,364	)		(1,364	)		—			—		—			—			(1,364	)		(1,364	)
Currency translation adjustments		—				—		—			1,403			—			1,403			—			—		—			1,403			—			1,403
Unrealized loss on marketable securities		—		��		—		—			(122	)		—			(122	)		—			—		—			(122	)		—			(122	)
Balance at June 30, 2021		72,008			$	—	$	506,304		$	(6,443	)	$	(95,045	)	$	404,816			72,008		$	—	$	506,304		$	(6,443	)	$	(95,045	)	$	404,816
Common stock issued upon exercise of options																				18			—		126			—			—			126
Vesting of restricted stock and performance stock units																				16			—		—			—			—			—
Purchase and retirement of common shares																				(4	)		—		(47	)		—			—			(47	)
Stock-based compensation																				—			—		2,218			—			—			2,218
Net loss																				—			—		—			—			(15,015	)		(15,015	)
Currency translation adjustments																				—			—		—			(4,117	)		—			(4,117	)
Unrealized loss on marketable securities																				—			—		—			(161	)		—			(161	)
Balance at September 30, 2021																				72,038		$	—	$	508,601		$	(10,721	)	$	(110,060	)	$	387,820

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation expense related to stock options for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 was $~~879~~1,213 and $~~521~~793, respectively.

The following table summarizes the stock option activity for the ~~six~~nine months ended ~~June~~September 30, 2022:


	Options
Outstanding on January 1, 2022		1,410
Granted		589
Exercised		(2	)
Expired		(20	)
Forfeited		(173	)
Outstanding on ~~June~~September 30, 2022		1,804

Compensation expense of $~~5,071~~7,047 and $~~2,066~~2,891 related to restricted shares was recognized during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively.

The following table summarizes time-vested restricted stock award and restricted stock unit activity for the ~~six~~nine months ended ~~June~~September 30, 2022:


	Units
Issued and unvested, January 1, 2022		701
Granted		~~2,782~~2,964
Vested		(~~571~~618	)
Forfeited		(~~249~~270	)
Issued and unvested, ~~June~~September 30, 2022		~~2,663~~2,777

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain employed for three years from the grant date. If the one-year target is achieved, the PSUs will then vest three years from grant date. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation expense of $~~854~~840 and $~~350~~1,471 related to PSUs was recognized during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively.

The following table summarizes the PSU activity for the ~~six~~nine months ended ~~June~~September 30, 2022:


	Units
Issued and unvested, January 1, 2022		622
Granted (1)		532
Performance adjustment (2)		36
Vested		(~~188~~207	)
Forfeited		(~~171~~200	)
Issued and unvested, ~~June~~September 30, 2022		~~831~~783

(1) Grant activity for all PSUs disclosed at target

(2) Reflects the performance adjustment based on actual performance measured at the end of the performance period

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. ~~NaN~~No shares were purchased and retired during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.

10. Transition costs

On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s former President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a transition agreement ("Transition Agreement") providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Dr. Tang’s service to the Company in all capacities ended on March 31, 2022.

Pursuant to the Transition Agreement, Dr. Tang received severance of $1,569, which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested

time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, we recognized a net $~~128~~0 and $1,508 of expense in relation to Dr. Tang's stock compensation during the three and ~~six~~nine months ended ~~June~~September 30, 2022, respectively.

On April 1, 2022 the Company's Board of Directors appointed Nancy J. Gagliano, M.D., M.B.A., to serve as the Company’s Interim Chief Executive Officer. In connection therewith, the Company and Dr. Gagliano entered into an employment agreement, dated as of March 21, 2022 (the “Employment Agreement”). Pursuant to the Employment Agreement, on April 1, 2022, Dr. Gagliano began receiving a monthly base salary of $56 per month and was also granted a one-time award of fully vested shares of the Company’s common stock with a grant date fair value of $100. Additionally, she was granted a one-time restricted stock unit award with a grant date fair value of $670 scheduled to vest in twelve equal monthly installments starting in April through her employment term, of which $168 vested during the three months ended June 30, 2022 and the remainder was forfeited when her employment ceased in June 2022.

On May 20, 2022, the Company entered into an employment agreement with Carrie Eglinton Manner, and in connection therewith, the Company's Board of Directors appointed Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022 (the “Effective Date”). Pursuant to the ~~Employment Agreement,~~employment agreement, Ms. Eglinton Manner’s initial annual base salary is $700 and she will participate in the Company’s annual incentive plan with a target annual incentive amount of at least 100% of her annual base salary. Additionally, she received inducement grants comprised of (i) a restricted stock unit award with a grant date fair value of $4,000, which vests on the second anniversary of the Effective Date (ii) a restricted stock award with a grant date fair value of $1,600, which vests annually starting on the first anniversary of the Effective Date and (iii) a PSU award, ~~with a grant date fair value of $1,600~~, which will be subject to the same vesting and performance conditions as are applicable to the 2022 performance-based restricted stock unit awards granted to the Company’s other executive officers.

11. Income Taxes

During the three and ~~six~~nine months ended ~~June~~September 30, 2022, we recorded an income tax expense (benefit) of $(~~1,169~~1,143) and $~~2,767~~1,624, respectively. Tax expense for the nine months ended September 30, 2022 includes $~~1,702~~1,683 of withholding tax ~~due~~paid on the repatriation of $65,000 of unremitted earnings from Canada to the United States. The remaining tax expense for the first ~~half~~nine months of 2022 is comprised of U.S. state income taxes of $~~400~~379 and a foreign ~~taxes~~tax benefit of $~~665~~438. During the three and ~~six~~nine months ended ~~June~~September 30, 2021, we recorded income tax expense of $~~3,610~~2,102 and $~~10,139~~12,241, respectively, which primarily consists of foreign tax expense. The decline in foreign tax expense in both periods of 2022 compared to 2021 is a result of the decrease in income before taxes generated by our Canadian subsidiary.

Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of ~~June~~September 30, 2022 and December 31, 2021 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes along with basis differences arising from accelerated tax depreciation of fixed assets.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both ~~June~~September 30, 2022 and December 31, 2021 since the facts and circumstances necessitating the allowance have not changed.

12. Commitments and Contingencies

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the ~~litigation.~~litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office. DNAG filed a motion to dismiss Spectrum’s counterclaims in October 2021, which was denied by the Court on March 30, 2022. Fact discovery is ongoing. The final pretrial conference is set for September 7, 2023.

13. Business Segment Information

Our business consists of 2two segments: our “Diagnostics” business, which primarily consists of the development, manufacture, and sale of rapid diagnostic tests used to determine if a person has a variety of infectious diseases including, HIV, HCV, and COVID-19. The Diagnostic business also manufactures and sells oral fluid substance abuse testing products. Our “Molecular Solutions” business is operated by our wholly-owned subsidiaries DNAG, Diversigen, and Novosanis. This segment of the business consists of the development, manufacture, and sale of kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. In addition, our Molecular Solutions business provides microbiome laboratory services.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 1). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. ~~Reportable segments have no inter-segment~~Inter-segment revenues and ~~inter-segment~~ expenses ~~have been~~are eliminated.

The following table summarizes operating segment information for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, and asset information as of ~~June~~September 30, 2022 and December 31, 2021:


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
Net revenues:
Diagnostics	$	60,455		$	19,311		$	98,765		$	33,857		$	97,651		$	23,511		$	196,416		$	57,368
Molecular Solutions		19,776			38,296			49,173			82,332			18,812			30,406			67,985			112,738
Total	$	80,231		$	57,607		$	147,938		$	116,189		$	116,463		$	53,917		$	264,401		$	170,106
Operating income (loss):
Diagnostics	$	(11,776	)	$	(11,850	)	$	(31,563	)	$	(23,967	)	$	11,289		$	(18,446	)	$	(20,274	)	$	(42,413	)
Molecular Solutions		(9,513	)		13,648			(5,704	)		36,187			(10,414	)		5,433			(16,118	)		41,620
Total	$	(21,289	)	$	1,798		$	(37,267	)	$	12,220		$	875		$	(13,013	)	$	(36,392	)	$	(793	)
Depreciation and amortization:
Diagnostics	$	1,903		$	939		$	3,630		$	1,829		$	2,112		$	1,136		$	5,742		$	2,965
Molecular Solutions		1,879			1,716			3,834			3,315			1,815			2,199			5,649			5,514
Total	$	3,782		$	2,655		$	7,464		$	5,144		$	3,927		$	3,335		$	11,391		$	8,479
Loss on impairment:
Diagnostics	$	8,517		$	—		$	8,517		$	—		$	—		$	—		$	8,517		$	—
Molecular Solutions		2,025			—			2,025			—			6,559			—			8,584			—
Total	$	10,542		$	—		$	10,542		$	—		$	6,559		$	—		$	17,101		$	—
Capital expenditures:
Diagnostics(1)	$	4,302		$	8,513		$	23,434		$	16,150		$	2,212		$	3,647		$	25,646		$	19,797
Molecular Solutions		919			3,355			2,006			6,779			429			932			2,435			7,711
Total	$	5,221		$	11,868		$	25,440		$	22,929		$	2,641		$	4,579		$	28,081		$	27,508

(1) Excludes $~~5,615~~4,902 and $~~33,803~~38,705 for purchases of property and equipment under government contracts for the three and ~~six~~nine months ended ~~June~~September 30, 2022, respectively.


	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Total assets:
Diagnostics	$	249,123	$	209,674	$	265,790	$	209,674
Molecular Solutions		180,131		251,316		166,418		251,316
Total	$	429,254	$	460,990	$	432,208	$	460,990

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings, losses, expenses, or other financial performance, future product performance or development, expected regulatory filings and approvals, planned business transactions, expected manufacturing performance, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include words such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to:

•

our ability to market and sell products, whether through our internal, direct sales force or third parties;

•

our ability to fulfill our commitments under our contracts with the U.S. government for InteliSwab® COVID-19 Rapid Tests;

•

the impact of significant customer concentration in the genomics business;

•

our ability to successfully scale-up our manufacturing for InteliSwab®COVID-19 Rapid Tests;

•

failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products;

•

our ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements;

•

our ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products;

•

our ability to comply with applicable regulatory requirements;

•

our ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (or “FDA”), or other regulators;

•

the potential impact of healthcare reform in the United States, including the Inflation Reduction Act of 2022, and measures being taken worldwide designed to reduce healthcare costs;

•

the impact of the COVID-19 pandemic on our business and labor force and supply chain;

•

our ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations, transport work-in-process goods and finished products and commercialize such products for COVID-19 testing;

•

changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements;

•

our ability to meet increased demand for our products;

•

our ability to diversify our customer base;

•

the impact of replacing distributors on our business;

•

inventory levels at distributors and other customers;

•

our ability to achieve our financial and strategic objectives and continue to increase our revenues, including the ability to expand international sales;

•

the impact of competitors, competing products and technology changes on our business;

•

reduction or deferral of public funding available to customers;

•

competition from new or better technology or lower cost products;

•

our ability to develop, commercialize and market new products;

•

market acceptance of oral fluid or urine testing, collection or other products;

•

market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services;

•

changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention, or (the “CDC”) or other agencies; ability to fund research and development and other products and operations;

•

our ability to obtain and maintain new or existing product distribution channels;

•

our reliance on sole supply sources for critical products and components;

•

the availability of related products produced by third parties or products required for use of our products;

•

the impact of contracting with the U.S. government on our business;

•

the impact of negative economic conditions on our business; including as a result of inflation, hostilities or war;

•

our ability to achieve and maintain sustained profitability;

•

our ability to increase our gross margins;

•

our ability to utilize net operating loss carry forwards or other deferred tax assets;

•

the volatility of our stock price;

•

uncertainty relating to patent protection and potential patent infringement claims;

•

uncertainty and costs of litigation relating to patents and other intellectual property;

•

the availability of licenses to patents or other technology;

•

our ability to enter into international manufacturing agreements;

•

obstacles to international marketing and manufacturing of products;

•

our ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms;

•

adverse movements in foreign currency exchange rates;

•

loss or impairment of sources of capital;

•

our ability to attract and retain qualified personnel;

•

our exposure to product liability and other types of litigation;

•

changes in international, federal or state laws and regulations;

•

customer consolidations and inventory practices;

•

equipment failures and ability to obtain needed raw materials and components;

•

~~the impact of terrorist attacks, civil unrest, hostilities and war;~~ and

•

general political, business and economic conditions.

These and other factors that could affect our results are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this Report, and we undertake no duty to update these statements.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of OraSure.

The following discussion should be read in conjunction with our consolidated financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.

Overview and Business Segments

The overall goal of our Company is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment and our “Molecular Solutions” segment.

Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Diagnostics business includes tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our COVID-19 and HIV products are also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and, in the case of the HIV product, as a self-test to individuals in a number of other countries. Through our Diagnostics business we are also developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis ("PrEP"), the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medications in a patient’s urine or blood, as well as point-of-care products currently in development. We began recording revenues on the sales of our InteliSwab® COVID-19 Rapid Tests during the third quarter of 2021.

Our Molecular Solutions business is operated by our wholly-owned subsidiaries, DNA Genotek Inc. ("DNAG"), Diversigen, Inc. ('Diversigen"), and Novosanis NV ("Novosanis"). Our Molecular Solutions business sells its products and services directly to its customers, primarily through its internal sales force in the U.S. domestic market, and in many international markets, also through distributors. Our products primarily consist of collection kits and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. Most of our Molecular Solutions revenues are derived from product sales to commercial customers and sales into the academic and research markets. A significant portion of our total sales is from repeat customers in both markets. Molecular Solutions customers span the disease risk management, diagnostics, pharmaceutical, biotech, companion animal and environmental markets.

~~We have~~In 2020, we expanded the market focus of our Molecular Solutions business by selling existing collection products for use with COVID-19 tests. ~~Demand~~In 2022, demand for COVID-19 PCR testing has declined driven by the availability of antigen tests and the wider availability of vaccines, thereby negatively impacting the sales of the collection products. We have also developed ~~new~~ collection devices for the emerging microbiome market, which focuses on studying ~~microbes~~microbiomes and their effect on human ~~health. Our primary product offering in the microbiome market, OMNIgene~~® ~~• GUT, is focused on the human gut microbiome (microbes living in human stool). In 2021, the OMNIgene~~® ~~• GUT collection device (OMD-200) was granted “FDA De Novo classification for the preservation~~ and stabilization of the relative abundance of microbial nucleic acids in clinical samples.” We leverage our existing sales force and global research connections to engage microbiome customers worldwide to establish ourselves among the leaders in ease-of-collection, stabilization, and transport of this challenging sample type.animal health.

Our Molecular Solutions segment includes the Colli-Pee® device, developed and sold by our Novosanis subsidiary, for the volumetric collection of first void urine. This product is in its early stages, and initial sales are occurring primarily through distributors and collaborations in the liquid biopsy and sexually transmitted disease markets. Our Molecular Solutions business also offers laboratory and analytical services for both genomics and microbiome customers to more fully meet their needs. These services are primarily provided to pharmaceutical, biotech companies, and research institutions.

Recent Developments

Impact of COVID-19

As COVID-19 continues to impact the economy of the United States and other countries around the world, we are committed to being a part of the response to this unprecedented challenge. We have made substantial investments to expand our operations in order to manufacture product used for COVID-19 testing in the United States.

Due to COVID-19, we have experienced volatility, including periods of material decline compared to prior year periods in testing volume of our base business (which excludes COVID-19 testing) and periods of significant demand for our COVID-19 testing product, with demand generally fluctuating in line with changes in prevalence of the virus and related variants. ItWhile demand for our COVID-19 PCR testing has declined in 2022, it is difficult for us to predict the duration or magnitude of the outbreak’s effects on our business or results of operations.

~~Appointment of New CEO~~BARDA Funding for Ebola Product

~~Carrie Eglinton Manner was appointed President~~In September 2022, we entered into an agreement with Biomedical Advanced Research and ~~Chief Executive Officer, effective June 4, 2022. Ms. Eglinton Manner also joined~~Development Authority ("BARDA"), which is part of the ~~OraSure Board~~office of ~~Directors (the "Board"~~the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services ("HHS")~~. She succeeded Dr. Nancy Gagliano, who was appointed interim CEO~~, pursuant to which BARDA will provide up to $8.6 million in ~~March 2022. Dr. Gagliano continues~~funding to ~~serve~~us to develop a 2nd generation Ebola test on the ~~OraSure Board.~~OraQuick® testing platform. Our current OraQuick® Ebola Rapid Antigen Test is de novo authorized for use with whole blood or cadaveric oral fluid. The test received de novo authorization from the FDA in 2019, making it the first and only rapid antigen test to receive authorization for the detection of Ebola virus.

New Contract for In-Home HIV Tests

~~Ms. Eglinton Manner, age 48, has years~~In September 2022, we were selected to provide our OraQuick® In-Home HIV tests in support of ~~leadership experience across multiple disciplines. Prior~~the Centers for Disease Control and Preventions (CDC) “Together Take Me Home,” HIV self-test program. Under the program, the CDC will provide $41.5 million over a five-year period to ~~joining~~support community testing. Emory University will manage the ~~Company, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostic~~program and Clinical Solutions at Quest Diagnostics since January 2017. Prior to Quest, Ms. Eglinton Manner spent over 20 years in various leadership roles in healthcare businesses at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices. She has served as a director of Repligen Corporation since June 2020. Ms. Eglinton Manner holds a B.S. in mechanical engineering from the University of Notre Dame.

~~Exploration of Strategic Alternatives~~

~~Ms. Eglinton Manner’s appointment as CEO came in tandem~~closely collaborate with a ~~decision~~number of partner organizations, including OraSure, to supply tests to communities not equitably reached by HIV testing services across the ~~OraSure Board~~United States.
Under the "Together Take Me Home" HIV self-test program, we will provide up to ~~conclude its previously announced review of strategic alternatives~~1 million OraQuick® In-Home HIV tests over a five-year period. Emory University and partner organizations will manage the program and provide logistical and distribution services for the ~~Company~~tests. A free HIV self-test will be mailed in discreet packages to ~~move forward under her leadership. Market conditions~~people who enroll through its website. The program will target populations that are disproportionately affected by HIV and ~~the Board’s belief in the Company’s ability~~less likely to ~~further build upon recent operational successes with Ms. Eglinton Manner’s leadership were factors in the decision.~~have access to key prevention services.

Current Consolidated Financial Results

During the ~~six~~nine months ended ~~June~~September 30, 2022, our consolidated net revenues increased ~~27%~~55% to ~~$147.9~~$264.4 million, compared to ~~$116.2~~$170.1 million for the ~~six~~nine months ended ~~June~~September 30, 2021. Net product and services revenues during the ~~six~~nine months ended ~~June~~September 30, 2022 increased ~~29%~~55% when compared to the same period of 2021, largely due to ~~the inclusion of $65.3~~$144.8 million of InteliSwab® COVID-19 rapid test ~~revenues.~~revenues recorded in the first nine months of 2022 compared to $7.9 million of revenue in the comparable period of 2021. We first began selling this product in August of ~~2021 resulting in no comparable~~2021. Also contributing to the increased revenues ~~in the first half~~were higher domestic sales of ~~2021.~~our HCV product and higher overall sales of our substance abuse testing and Colli-Pee® products. Declines in sales of our molecular sample collection kits for COVID-19 testing, lower laboratory services revenues, and a decline in ~~domestic~~international sales of our HIV products partially offset ~~this~~these positive ~~driver~~drivers of revenue. Other revenues for the ~~six~~nine months ended ~~June~~September 30, 2022 were ~~$3.5~~$7.2 million compared to ~~$3.9~~$4.6 million in the same period of 2021. This ~~decrease~~increase was largely due to ~~lower~~higher research and development funding associated with our InteliSwab® COVID-19 rapid test offset by a decrease in royalty income.

Our consolidated net loss for the ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$38.8~~$33.5 million, or ~~$0.54~~$0.46 per share on a fully diluted basis, compared to a consolidated net ~~income~~loss of ~~$2.4~~$12.6 million, or ~~$0.03~~$0.18 per share on a fully diluted basis, for the ~~six~~nine months ended ~~June~~September 30, 2021. Results for the ~~six~~nine months ended ~~June~~September 30, 2022 were impacted by lower gross margins rates caused by an unfavorable product mix of higher sales of lower margin products, increases in inventory reserves associated with excess inventory levels and manufacturing inefficiencies that occurred in the first quarter of 2022, lower absorption of labor costs that also occurred in the first half of 2022 and the absence of the Gates subsidy which expired in June 2021. Also contributing to our net loss is an increase in operating expense as a result of impairment charges taken ~~in the second quarter of 2022~~ on idle manufacturing lines and goodwill, higher legal fees, severance charges and accelerated stock compensation expense associated with our CEO transition and termination of our general counsel, increased staffing costs due to overall higher headcount, and nonrecurring costs associated with our strategic alternatives process.

Cash used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$45.5 million. Cash~~$29.2 million compared to cash used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2021 ~~was $3.5~~of $22.6 million. During the first ~~half~~nine months of 2022, our cash flow used in operating activities increased ~~significantly~~ as a result of our net loss and increased working capital requirements as we ~~scale~~scaled our InteliSwab® manufacturing capacity to meet higher demand. As of ~~June~~September 30, 2022, we had ~~$95.8~~$101.6 million in cash, cash equivalents and available-for-sale securities.

Results of Operations

Three months ended ~~June~~September 30, 2022 compared to ~~June~~September 30, 2021

CONSOLIDATED NET REVENUES

The table below shows a breakdown of total consolidated net revenues (dollars in thousands) generated by each of our business segments during the three months ended ~~June~~September 30, 2022 and 2021.


	For the Three Months Ended June 30,														For the Three Months Ended September 30,
	Dollars								Percentage of Total Net Revenues						Dollars								Percentage of Total Net Revenues
	2022		2021		% Change				2022			2021			2022		2021		% Change				2022			2021
Diagnostics	$	59,976	$	18,252		229		%		75	%		32	%	$	94,402	$	23,281		305		%		81	%		43	%
Molecular Solutions		19,191		37,489		(49	)			24			65			18,419		29,948		(38	)			16			56
Net product and services revenues		79,167		55,741		42				99			97			112,821		53,229		112				97			99
Other		1,064		1,866		(43	)			1			3			3,642		688		429				3			1
Net revenues	$	80,231	$	57,607		39		%		100	%		100	%	$	116,463	$	53,917		116		%		100	%		100	%

Consolidated net product and services revenues increased ~~42%~~112% to ~~$79.2~~$112.8 million for the three months ended ~~June~~September 30, 2022 from ~~$55.7~~$53.2 million for the three months ended ~~June~~September 30, 2021. The increase in revenues is largely due to ~~the inclusion of $43.1~~$79.6 million of InteliSwab® COVID-19 rapid test ~~revenues.~~revenues in the third quarter of 2022 compared to $7.7 million in the third quarter of 2021. We first began selling this product in August of ~~2021 resulting~~2021. Higher sales of our HCV product also contributed to the increased revenues. Declines in ~~no comparable~~ revenues ~~in the second quarter of 2021. Declines in~~across all other product lines partially

~~revenues across all other product line partially~~ offset this positive driver of revenue. Other revenues for the three months ended ~~June~~September 30, 2022 ~~decreased 43%~~increased 429% to ~~$1.1~~$3.6 million from ~~$1.9 million~~$688,000 for the three months ended ~~June~~September 30, 2021 due to ~~lower~~higher research and development funding associated with the development of our InteliSwab® COVID-19 rapid ~~test and lower royalty income.~~test.

Consolidated net revenues derived from products sold to customers outside of the United States were ~~$9.9~~$7.5 million and ~~$10.0~~$10.9 million, or ~~12%~~6% and ~~17%~~20% of total net revenues, for the three months ended ~~June~~September 30, 2022 and 2021, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total consolidated net revenues.

Net Revenues by Segment

Diagnostics Segment

The table below shows a breakdown of total net revenues (dollars in thousands) generated by our Diagnostics segment during the three months ended ~~June~~September 30, 2022 and 2021.


	For the Three Months Ended June 30,														For the Three Months Ended September 30,
	Dollars								Percentage of Total Net Revenues						Dollars								Percentage of Total Net Revenues
Market	2022		2021		% Change				2022			2021			2022		2021		% Change				2022			2021
Infectious disease testing:
COVID-19	$	43,114	$	89	NM			%		71	%		0	%	$	79,559	$	7,675		937		%		81	%		33	%
Other		14,232		15,534		(8	)			23			80			12,248		12,932		(5	)			12			55
Total infectious disease testing		57,346		15,623		267				95			81			91,807		20,607		346				94			88
Substance abuse testing		2,630		2,629		0				4			14			2,595		2,674		(3	)			3			11
Net product revenues		59,976		18,252		229				99			95			94,402		23,281		305				97			99
Other		479		1,059		(55	)			1			5			3,249		230	NM					3			1
Net revenues	$	60,455	$	19,311		213		%		100	%		100	%	$	97,651	$	23,511		315		%		100	%		100	%

NM - not meaningful

Infectious Disease Testing Market

COVID-19 revenues were ~~$43.1~~$79.6 million for the three months ended ~~June~~September 30, 2022, driven by sales of our InteliSwab® COVID-19 rapid test. We first began selling this product in August of ~~2021 and there are no comparable sales in the second quarter of~~ 2021.

Sales to the other infectious disease testing markets decreased 8%5% to ~~$14.2~~$12.2 million for the three months ended ~~June~~September 30, 2022 from ~~$15.5~~$12.9 million for the three months ended ~~June~~September 30, 2021. This decrease resulted from lower ~~worldwide~~international sales of our OraQuick® HIV product offset by increased domestic sales of the same product and ~~international~~higher world-wide OraQuick® HCV product sales.

The table below shows a breakdown of our total net OraQuick® HIV and HCV product revenues (dollars in thousands) during the three months ended ~~June~~September 30, 2022 and 2021.


	For the Three Months Ended June 30,								For the Three Months Ended September 30,
Market	2022		2021		% Change				2022		2021		% Change
Domestic HIV	$	3,741	$	4,135		(10	)	%	$	4,609	$	3,440		34		%
International HIV		6,616		6,809		(3	)		��	4,445		6,582		(32	)
Net HIV revenues		10,357		10,944		(5	)			9,054		10,022		(10	)
Domestic HCV		2,537		2,571		(1	)			1,866		1,827		2
International HCV		1,154		1,729		(33	)			1,368		888		54
Net HCV revenues		3,691		4,300		(14	)			3,234		2,715		19
Net OraQuick® revenues	$	14,048	$	15,244		(8	)	%	$	12,288	$	12,737		(4	)	%

Domestic OraQuick® HIV sales ~~decreased 10%~~increased 34% to ~~$3.7~~$4.6 million for the three months ended ~~June~~September 30, 2022 from ~~$4.1~~$3.4 million for the three months ended ~~June~~September 30, 2021, primarily as a result of ~~a large second quarter 2021 order~~an increase in new customers driven by our distributor channel and an increase in sales of our OraQuick® In-Home HIV test ~~shipped~~sold to ~~the CDC and used in an initiative~~public health agencies as demand shifts from in-person testing to ~~drive increased~~ in-home ~~HIV~~ testing. ~~A similar order did not occur in the second quarter of 2022.~~

International sales of our OraQuick® HIV tests decreased 3%32% to $4.4 million for the three months ended September 30, 2022 from $6.6 million for the three months ended ~~June 30, 2022 from $6.8 million for the three months ended June~~September 30, 2021 largely due to the absence of the Gates Foundation subsidy which expired in June 2021 and is not included in revenues in the second quarter of 2022, initial stocking orders into Asia that did not recur in 2022, and the impact of the Russian and Ukraine war. These decline in revenues were partially offset by increased sales into Africa as the COVID-19 impact lessens.customer ordering patterns.

Domestic OraQuick® HCV sales remained largely flat at ~~$2.5~~$1.9 million for the three months ended ~~June~~September 30, 2022 compared to ~~$2.6~~$1.8 million for the three months ended ~~June~~September 30, 2021.

International OraQuick® HCV sales ~~decreased 33~~increased 54 % to ~~$1.2~~$1.4 million for the three months ended ~~June~~September 30, 2022 compared to ~~$1.7 million~~$888,000 for the three months ended ~~June~~September 30, 2021 due to a ~~stock order into Korea which did no repeat~~recovery in ~~2022.~~ordering by certain countries post the COVID-19 impact.

Substance Abuse Testing Market

Sales to the substance abuse testing assessment market remained largely flat at $2.6 million for ~~both~~ the three months ended ~~June~~September 30, 2022 ~~and~~compared to $2.7 million for the three months ended September 30, 2021.

Other Revenues

Other revenues for the three months ended ~~June~~September 30, 2022 ~~decreased 55%~~increased to ~~$479,000~~$3.2 million from ~~$1.1 million~~$230,000 for the three months ended ~~June~~September 30, 2021, due to ~~lower~~higher research and development funding associated with our InteliSwab® COVID-19 rapid test.

Molecular Solutions Segment

The table below shows a breakdown of our total net revenues (dollars in thousands) during the three months ended ~~June~~September 30, 2022 and 2021.


		For the Three Months Ended June 30,									For the Three Months Ended September 30,
Market	Market	2022		2021		% Change				Market	2022		2021		% Change
Genomics		$	15,486	$	19,498		(21	)	%		$	13,980	$	19,018		(26	)	%
Microbiome			1,832		2,447		(25	)				1,761		1,693		4
COVID-19			264		11,981		(98	)				361		6,255		(94	)
Laboratory services			1,204		3,114		(61	)				1,957		2,406		(19	)
Other product and service revenues			405		449		(10	)				360		576		(38	)
Net molecular product and services revenues		$	19,191		37,489		(49	)			$	18,419		29,948		(38	)
Other			585		807		(28	)				393		458		(14	)
Net molecular revenues		$	19,776	$	38,296		(48	)	%		$	18,812	$	30,406		(38	)	%

Sales of our genomics products decreased ~~21%~~26% to ~~$15.5~~$14.0 million for the three months ended ~~June~~September 30, 2022, compared to ~~$19.5~~$19.0 million for the three months ended ~~June~~September 30, 2021, as result of customer ordering ~~patterns.~~patterns and a shift in market prioritization at our larger commercial customers.

Microbiome kit sales ~~decreased 25%~~increased 4% to $1.8 million for the three months ended ~~June~~September 30, 2022 compared to ~~$2.4~~$1.7 million for the three months ended ~~June~~September 30, 2021, due to ~~lower sales to certain Clinical Research Organizations ("CROs") as a result~~renewal of ~~delays in microbiome~~ clinical ~~studies.~~study activities, new customer accounts offset by other customer ordering patterns.

Sales of our molecular sample collection kits for COVID-19 testing decreased ~~98%~~94% to ~~$264,000~~$0.3 million for the three months ended ~~June~~September 30, 2022 compared to ~~$12.0~~$6.3 million during the comparable period in 2021 due to lower COVID-19 PCR testing sales to our core customers, driven by the availability of antigen tests, the wider availability of vaccines and high inventory levels held by some of those customers and the termination of public funding for PCR testing.

Laboratory services revenues declined ~~61%~~19% to ~~$1.2~~$2.0 million for the three months ended ~~June~~September 30, 2022 compared to ~~$3.1~~$2.4 million for the three months ended ~~June~~September 30, 2021 as a result of a large customer ceasing its operations and ~~due to timing~~a decline in clinical trial work at certain pharmaceutical customers, partially offset by the addition of ~~clinical trials.~~new customer accounts.

Other product and service revenues ~~remained largely unchanged at $405,000~~declined 38% to $0.3 million in the ~~second~~third quarter of 2022 compared to ~~$449,000~~$576,000 in the ~~second~~third quarter of ~~2021.~~2021 largely due to the timing of customer orders.

Other revenues for the three months ended ~~June~~September 30, 2022 decreased ~~28%~~14% to ~~$585,000~~$0.4 million from ~~$807,000~~$0.5 million for the three months ended ~~June~~September 30, 2021, largely as a result of lower royalty income received under a litigation settlement agreement.

CONSOLIDATED OPERATING RESULTS

Consolidated gross profit margins ~~were 34%~~remained flat at 40% for both the three months ended September 30, 2022 and 2021.

Consolidated operating income for the three months ended June 30, 2022 compared to 53% for the three months ended June 30, 2021. The decrease in gross profit margins was primarily due to a less favorable product mix and increased scrap expense associated with reserves for excess inventory.

~~Consolidated operating loss for the three months ended June~~September 30, 2022 was ~~$21.3~~$875 thousand, a $13.9 million ~~a $23.1 million decrease~~increase from the ~~$1.8~~$13.0 million operating ~~income~~loss reported for the three months ended ~~June~~September 30, 2021. Results for the three months ended ~~June~~September 30, 2022 were ~~negatively~~positively impacted by the

~~lower gross profit margin~~ increase in revenues described above ~~coupled~~partially offset by impairment charges of $6.6 million associated with idle manufacturing lines associated with our molecular business and by an increase in operating expenses as described ~~below, including an aggregate impairment charge of $10.5 million.~~below.

OPERATING INCOME (LOSS) BY SEGMENT

We evaluate performance of our operating segments based on revenue and operating income. Reportable segments have no inter-segment revenue and ~~inter-segment~~ expenses that are eliminated in consolidation, including the fees associated with an intercompany service agreement between the U.S. and Canadian entities.

Diagnostics Segment

The gross profit margin for the Diagnostics segment was ~~36%~~38% for the three months ended ~~June~~September 30, 2022 compared to ~~34%~~16% for the three months ended ~~June~~September 30, 2021. This increase is due to improved product mix of higher margin product sales ~~partially offset by~~and the ~~June~~improved quality-yield experienced as compared to the scale-up and production issues experienced in the third quarter of 2021 ~~expiration~~related to the manufacturing of ~~subsidies under~~InteliSwab® tests which caused higher than normal scrap rates. In addition, the ~~support agreement with~~third quarter of 2021 included a reserve for COVID-19 antibody inventory that did not recur in the ~~Gates Foundation.~~third quarter of 2022. Also contributing to the higher margins is the increase in non-product revenues which contributes 100% to the gross margin rate.

Research and development expenses increased 26% to ~~$6.3~~$7.4 million for the three months ended ~~June~~September 30, 2022 compared to ~~$5.0~~$5.9 million for the three months ended ~~June~~September 30, 2021 largely due to ~~increased staffing costs associated with higher head count,~~ increased clinical study activities related to obtaining CE mark for our InteliSwab® rapid test and ~~higher subscription~~increased staffing costs associated with ~~our new quality system.~~higher head count. Sales and marketing expenses increased ~~19%~~8% to ~~$7.8~~$9.7 million for three months ended ~~June~~September 30, 2022 from ~~$6.6~~$9.0 million for the three months ended ~~June~~September 30, 2021 due to an increase in our reserve for uncollectible accounts, increased staffing costs associated with higher head count and increased travel ~~trade show, and annual meetings~~ expenses as travel and in person events have resumed as COVID-19 restrictions have been lifted. These increases in spend were partially offset by a decline in consulting spend associated with business strategy work that occurred in 2021 and did not repeat in 2022 and lower advertising and market research costs associated with our InteliSwab® test. General and administrative expenses increased ~~54%~~5% to ~~$11.0~~$8.9 million for the three months ended ~~June~~September 30, 2022 from ~~$7.1~~$8.1 million for the three months ended ~~June~~September 30, 2021 largely due to severance costs and accelerated stock compensation expense associated with our former general counsel's employment and termination agreements, stock compensation costs associated with restricted stock awards granted to certain board members with immediate vesting provisions, and higher legal, accounting, and information technologies contract fees.

Operating expenses for the Diagnostic segment also include an impairment charge of $4.9 million associated with an idle manufacturing line for which it has no projected cash flow and minimal resale or salvage value. Diagnostic operating expenses also included a goodwill impairment charge of $3.6 million. The decline in the Company's stock price was identified as a triggering event which required the Company to perform an quantitative goodwill impairment analysis. The results of this analysis indicated the Diagnostic segment's goodwill was impaired and was written down to $0.increased staffing costs.

All of the above contributed to the Diagnostics segment’s operating ~~loss~~income of ~~$11.8~~$11.3 million for the three months ended ~~June~~September 30, 2022, which included the non-cash impairment charges of $8.5 million, non-cash charges of ~~$1.9~~$2.1 million for depreciation and amortization and ~~$2.8~~$1.6 million for stock-based compensation. The Diagnostics segment operating loss in the ~~second~~third quarter of 2021 included a ~~$220,000~~$1.5 million non-cash pre-tax benefit associated with the change in the fair value of acquisition-related contingent consideration. There was no similar benefit recorded in the ~~second~~third quarter of 2022.

Molecular Solutions Segment

The gross profit margin for the Molecular Solutions segment was ~~31%~~49% for the three months ended ~~June~~September 30, 2022 compared to ~~63%~~58% for the three months ended ~~June~~September 30, 2021. This decrease was due to ~~an increase in reserves for excess inventory as result of a forecasted decline in demand of certain products used in COVID PCR testing and~~ a less favorable product mix.

Research and development expenses ~~remained relatively flat at $2.8~~decreased 13% to $2.4 million for the three months ended ~~June~~September 30, 2022 from $2.7 million for the three months ended ~~June~~September 30, 2021 .largely due to a decline in non-cash stock compensation expense. Sales and marketing expenses ~~also remained flat at $3.9~~decreased 23% to $3.8 million for the three months ended ~~June~~September 30, 2022 from $4.9 million for the three months ended September 30, 2021 largely due to a decline in consulting spend associated with business strategy work that occurred in 2021 and did not repeat in 2022, a decrease in expense related to the cancellation of a marketing loyalty program, and lower amortization expense as related intangibles were fully amortized at the end of 2021. General and administrative expenses increased ~~70%~~58% to ~~$6.6~~$7.0 million for the three months ended ~~June~~September 30, 2022 from ~~$3.9~~$4.4 million for the three months ended ~~June~~September 30, 2021 largely due to higher legal fees, increased ~~legal fees.~~non-cash stock compensation costs, and penalties and interest recorded related to a sales tax audit that did not occur in 2021.

Operating expenses for the Molecular segment also include an impairment charge of ~~$2.0~~$6.6 million for the three months ended ~~June~~September 30, 2022 associated with ~~two~~several idle manufacturing lines for which there are no projected cash flow and minimal resale or salvage value.

All of the above contributed to the Molecular Solutions segment’s operating loss of ~~$9.5~~$10.4 million for the three months ended ~~June~~September 30, 2022, which included the non-cash impairment charge of ~~$2.0~~$6.6 million, non-cash charges of ~~$1.9~~$1.8 million for depreciation and amortization and ~~$529,000~~$0.7 million for stock-based compensation.

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established against our total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the three months ended ~~June~~September 30, 2022, we recorded a U.S. state tax ~~expense~~benefit of ~~$183,000~~$40,000 compared to ~~$54,000 of state income tax benefit~~$102,000 for the three months ended ~~June~~September 30, 2021. For the three months ended ~~June~~September 30, 2022, we recorded a foreign tax benefit of ~~$1.3~~$1.1 million compared to foreign tax expense of ~~$3.7~~$2.2 million for the three months ended ~~June~~September 30, 2021. This overall decrease in foreign tax expense is largely a result of the decrease in income before taxes generated by our Canadian subsidiary.

~~Six~~Nine months ended ~~June~~September 30, 2022 compared to ~~June~~September 30, 2021

CONSOLIDATED NET REVENUES

The table below shows a breakdown of total consolidated net revenues (dollars in thousands) generated by each of our business segments during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.


	For the Six Months Ended June 30,														For the Nine Months Ended September 30,
	Dollars								Percentage of Total Net Revenues						Dollars								Percentage of Total Net Revenues
	2022		2021		% Change				2022			2021			2022		2021		% Change				2022			2021
Diagnostics	$	96,372	$	31,585		205		%		65	%		27	%	$	190,774	$	54,867		248		%		72	%		32	%
Molecular Solutions		48,031		80,735		(41	)			33			69			66,450		110,682		(40	)			26			65
Net product and services revenues		144,403		112,320		29				98			96			257,224		165,549		55				98			97
Other		3,535		3,869		(9	)			2			4			7,177		4,557		57				3			4
Net revenues	$	147,938	$	116,189		27		%		100	%		100	%	$	264,401	$	170,106		55		%		101	%		101	%

Consolidated net product and services revenues increased ~~29%~~55% to ~~$144.4~~$257.2 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$112.3~~$165.5 million for the ~~six~~nine months ended ~~June~~September 30, 2021. The increase in revenues is largely due to ~~the inclusion of $65.3~~$144.8 million of InteliSwab® COVID-19 rapid test ~~revenues.~~revenues recorded in the first nine months of 2022 compared to $7.9 million of revenue in the comparable period of 2021. We first began selling this product in August of ~~2021 resulting in no comparable~~2021. Also contributing to the increased revenues ~~in the first half~~were higher domestic sales of ~~2021.~~our HCV product and higher overall sales of our substance abuse testing and Colli-Pee® products. Declines in sales of our molecular sample collection kits for COVID-19 testing, lower laboratory services revenues, and a decline in international sales of our HIV products partially offset ~~this~~these positive ~~driver~~drivers of revenue. Other revenues for the ~~six~~nine months ended ~~June~~September 30, 2022 ~~decreased 9%~~were $7.2 million compared to ~~$3.5~~$4.6 million ~~from $3.9 million for~~in the ~~six months ended June 30, 2021~~same period of 2021. This increase was largely due to ~~lower~~higher research and development funding associated with our InteliSwab® COVID-19 rapid test offset by a decrease in royalty income.

Consolidated net revenues derived from products sold to customers outside of the United States were ~~$19.6~~$27.2 million and ~~$19.5~~$30.4 million, or ~~13%~~10% and ~~17%~~18% of total net revenues, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total consolidated net revenues.

Net Revenues by Segment

Diagnostics Segment

The table below shows a breakdown of total net revenues (dollars in thousands) generated by our Diagnostics segment during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.


	For the Six Months Ended June 30,														For the Nine Months Ended September 30,
	Dollars								Percentage of Total Net Revenues						Dollars								Percentage of Total Net Revenues
Market	2022		2021		% Change				2021			2020			2022		2021		% Change				2021			2020
Infectious disease testing:
COVID-19	$	65,250	$	262	NM			%		66	%		0	%	$	144,809	$	7,938	NM			%		74	%		0	%
Other		25,931		26,732		(3	)			25			79			38,179		39,664		(4	)			18			69
Total infectious disease testing		91,181		26,994		238				92			80			182,988		47,602		284				93			83
Substance abuse testing		5,191		4,591		13				5			14			7,786		7,265		7				4			13
Net product revenues		96,372		31,585		205				97			94			190,774		54,867		248				97			96
Other		2,393		2,272		5				3			6			5,642		2,501		126				4			3
Net revenues	$	98,765	$	33,857		192		%		100	%		100	%	$	196,416	$	57,368		242		%		101	%		99	%

NM - not meaningful

Infectious Disease Testing Market

COVID-19 revenues were ~~$65.3~~$144.8 million for the ~~six~~nine months ended ~~June~~September 30, 2022, compared to $7.9 million for the nine months ended September 30, 2021. This increase was driven by sales of our InteliSwab® COVID-19 rapid ~~test. We~~test which we first began selling ~~this product~~ in August of ~~2021 and there are no comparable sales in the first half of~~ 2021.

Sales to the other infectious disease testing markets decreased 3%4% to ~~$25.9~~$38.2 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$26.7~~$39.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021. This decrease resulted from lower ~~domestic~~world-wide OraQuick® HIV and international OraQuick® HCV product sales, partially offset by higher ~~international OraQuick~~® ~~HIV and~~ domestic OraQuick® HCV sales.

The table below shows a breakdown of our total net OraQuick® HIV and HCV product revenues (dollars in thousands) during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.


	Six Months Ended June 30,								Nine Months Ended September 30,
Market	2022		2021		% Change				2022		2021		% Change
Domestic HIV	$	7,506	$	9,050		(17	)	%	$	12,115	$	12,490		(3	)	%
International HIV		11,017		10,672		3				15,462		17,255		(10	)
Net HIV revenues		18,523		19,722		(6	)			27,577		29,745		(7	)
Domestic HCV		4,574		3,754		22				6,440		5,580		15
International HCV		2,374		2,914		(19	)			3,742		3,802		(2	)
Net HCV revenues		6,948		6,668		4				10,182		9,382		9
Net OraQuick® revenues	$	25,471	$	26,390		(3	)	%	$	37,759	$	39,127		(3	)	%

Domestic OraQuick® HIV sales decreased ~~17%~~3% to ~~$7.5~~$12.1 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$9.1~~$12.5 million for the ~~six~~nine months ended ~~June~~September 30, 2021, primarily as a result of a large order fulfilled in the first half of 2021 for our OraQuick® In-Home HIV test shipped to the CDC and used in an initiative to drive increased in-home HIV testing. A similar order did not occur induring the ~~first half of~~nine months ended September 30, 2022.

International sales of our OraQuick® HIV tests ~~increased 3%~~decreased 10% to ~~$11.0~~$15.5 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$10.7~~$17.3 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to ~~increased sales into Africa as the COVID-19 impact lessens. This increase to revenues was partially offset by~~customer ordering patterns and the absence of the Gates Foundation subsidy, which expired in June 2021 and is not included in revenues in ~~the first quarter of 2022, as well as the impact of the Russia and Ukraine war.~~2022.

Domestic OraQuick® HCV sales increased ~~22%~~15% to ~~$4.6~~$6.4 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$3.8~~$5.6 million for the ~~six~~nine months ended ~~June~~September 30, 2021, driven by new funding granted by certain state governments, increased legislation regarding drug testing and a rise in drug use requiring more testing.

International OraQuick® HCV sales ~~decreased 19% to $2.4~~remained largely flat at $3.7 million for the ~~six~~nine months ended ~~June~~September 30, 2022 ~~from $2.9~~compared to $3.8 million for the ~~six~~nine months ended ~~June~~September 30, ~~2021 due to large stock ordering shipped to Korea that did not repeat in 2022.~~2021.

Sales to the substance abuse testing assessment market increased ~~13%~~7% to ~~$5.2~~$7.8 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$4.6~~$7.3 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to market share gains.

Other Revenues

Other revenues for the ~~six~~nine months ended ~~June~~September 30, 2022 increased ~~minimally~~ to ~~$2.4~~$5.6 million from ~~$2.3~~$2.5 million for the ~~six~~nine months ended ~~June~~September 30, 2021, due to higher research and development funding for 510(k) clearance and CLIA waiver of our InteliSwab® COVID-19 rapid test partially offset by lower royalty income.

Molecular Solutions Segment

The table below shows a breakdown of our total net revenues (dollars in thousands) during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.

Six Months Ended June 30,

Market
2022

2021

% Change

Genomics

$
30,578

$
30,316

1

%
Microbiome

3,822

4,198

(9
)

COVID-19

9,161

39,953

(77
)

Laboratory services

2,938

5,611

(48
)

Other product revenues

1,532

657

133

Net molecular product and services revenues

$
48,031

$
80,735

(41
)

Other

1,142

1,597

(28
)

Net molecular product and services revenues

$
49,173

$
82,332

(40
)
%


	Nine Months Ended September 30,
Market	2022		2021		% Change
Genomics	$	44,558	$	49,333		(10	)	%
Microbiome		5,583		5,888		(5	)
COVID-19		9,522		46,209		(79	)
Laboratory services		4,895		8,017		(39	)
Other product revenues		1,892		1,235		53
Net molecular product and services revenues	$	66,450	$	110,682		(40	)
Other		1,535		2,056		(25	)
Net molecular product and services revenues	$	67,985	$	112,738		(40	)	%

Sales of our genomics products ~~remained largely flat and increased only 1%~~decreased 10% to ~~$30.6~~$44.6 million for the ~~six~~nine months ended ~~June~~September 30, 2022, compared to ~~$30.3~~$49.3 million for the ~~six~~nine months ended ~~June~~September 30, ~~2021.~~2021 largely as a result of customer ordering patterns and a shift in market prioritization at our larger commercial customers.

Microbiome kit sales decreased 9%5% to ~~$3.8~~$5.6 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$4.2~~$5.9 million for the ~~six~~nine months ended ~~June~~September 30, 2021, due to ~~a decline in revenues to CROs driven by the timing of microbiome clinical studies.~~customer ordering patterns.

Sales of our molecular sample collection kits for COVID-19 testing decreased ~~77%~~79% to ~~$9.2~~$9.5 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$40.0~~$46.2 million during the comparable period in 2021 due to lower COVID-19 PCR testing sales to our core customers, driven by the availability of antigen tests, the wider availability of vaccines, lower public funding for PCR testing, and high inventory levels held by some of those customers.

Laboratory services revenues declined ~~48%~~39% to ~~$2.9~~$4.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$5.6~~$8.0 million for the ~~six~~nine months ended ~~June~~September 30, 2021 as a result of a large customer ceasing its operations and a slowdown in clinical trials.

Other product and service revenues increased ~~133%~~53% to ~~$1.5~~$1.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$657,000~~$1.2 million for the ~~six~~nine months ended ~~June~~September 30, 2021 largely due to increased sales by our Novosanis subsidiary.

Other revenues for the ~~six~~nine months ended ~~June~~September 30, 2022 decreased ~~28%~~25% to ~~$1.1~~$1.5 million from ~~$1.6~~$2.1 million for the ~~six~~nine months ended ~~June~~September 30, 2021, largely as a result of lower royalty income received under a litigation settlement agreement.

CONSOLIDATED OPERATING RESULTS

Consolidated gross profit margins were ~~35%~~37% for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~59%~~53% for the ~~six~~nine months ended ~~June~~September 30, 2021. The decrease in gross ~~profit~~ margins rates was caused by an unfavorable product mix of higher sales of lower margin ~~product,~~products, increases in inventory reserves associated with excess inventory levels and manufacturing inefficiencies that occurred in the first quarter of 2022, lower absorption of labor costs that also occurred in the first half of 2022 and the absence of the Gates Foundation subsidy which expired in June 2021.

Consolidated operating loss for the ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$37.3~~$36.4 million, a ~~$49.5~~$35.6 million decrease from the ~~$12.2 million operating income reported~~$793 thousand recorded for the ~~six~~nine months ended ~~June~~September 30, 2021. Results ~~for the six months ended June 30,~~in 2022were negatively impacted by the lower gross profit margin described above coupled with an increase in operating expenses as described below, including an aggregate impairment charge of ~~$10.5~~$17.1 million.

OPERATING INCOME (LOSS) BY SEGMENT

Diagnostics Segment

The gross profit margin for the Diagnostics segment was ~~29%~~33% for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~38%~~29% for the ~~six~~nine months ended ~~June~~September 30, 2021. This ~~decrease~~improvement in margin is ~~due~~a result of a more favorable product mix, the increase in non-product revenues which contribute 100% to ~~inefficiencies~~the gross margin rate partially offset by increases in ~~our InteliSwab~~® ~~manufacturing process experienced in the beginning of the year causing high~~ scrap ~~rates, under-absorption~~and lower absorption of labor costs associated with the manufacturing inefficiencies that occurred earlier in 2022 that have since been corrected and the June 2021 expiration of subsidies under the support agreement with the Gates ~~Foundation, and a less favorable product mix.~~Foundation.

Research and development expenses increased 2%10% to ~~$11.8~~$19.2 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$11.5~~$17.4 million for the ~~six~~nine months ended ~~June~~September 30, 2021 largely due to higher staffing costs associated with increased head count, increased clinical study activities related to obtaining CE mark for our InteliSwab® rapid test, partially offset by lower product development activities related to our InteliSwab® rapid test ~~which did not repeat in the first half of 2022~~ as we received EUA authorization in June 2021. Sales and marketing expenses increased ~~25%~~18% to ~~$15.9~~$25.6 million for ~~six~~the nine months ended ~~June~~September 30, 2022 from ~~$12.8~~$21.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to increased staffing costs associated with higher head count, increased travel and annual ~~meetings~~meeting expenses as travel and in person events have resumed as COVID-19 restrictions have been lifted, increased consultant costs, ~~higher advertising~~ and ~~market research expenses and higher subscription costs associated with our new CRM system. This~~an increase ~~in spending was partially offset by a decline~~ in our reserve for uncollectible accounts, ~~lower recruiting fees and~~partially offset by a decrease in commission expense. General and administrative expenses increased ~~82%~~55% to ~~$24.7~~$33.6 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$13.6~~$21.6 million for the ~~six~~nine months ended ~~June~~September 30, 2021 largely due to higher staffing costs associated with increased ~~consulting costs,~~head count, higher stock compensation expense associated with accelerated vesting of shares under our former CEO's and general counsel's employment agreements, ~~higher staffing~~increased consulting costs, ~~associated with increased head count,~~ increased legal costs, higher severance costs, ~~associated with our former general counsel,~~and increased accounting ~~fees, and higher recruitment expense largely associated with our CEO search.~~fees.

Operating expenses for the Diagnostic segment also include an impairment charge of $4.9 million associated with an idle manufacturing line for which it has no projected cash ~~flow~~flows and minimal resale or salvage value. Diagnostic operating expenses also included a goodwill impairment charge of $3.6 million. The decline in the Company's stock price was identified as a triggering event which required the Company to perform ana quantitative goodwill impairment analysis. The results of this analysis indicated the Diagnostic segment's goodwill was impaired and was written down to $0.

All of the above contributed to the Diagnostics segment’s operating loss of ~~$31.6~~$20.3 million for the ~~six~~nine months ended ~~June~~September 30, 2022, which included the non-cash impairment charge of $8.5 million, non-cash charges of ~~$3.6~~$5.7 million for depreciation and amortization and ~~$5.9~~$7.5 million for stock-based compensation. The Diagnostics segment operating loss also included a non-cash pre-tax benefit of $36,000 associated with the change in the fair value of acquisition-related contingent consideration. This is in comparison to an $1.0 million benefit recorded in the first half of 2021.

Molecular Solutions Segment

The gross profit margin for the Molecular Solutions segment was 47% for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~68%~~66% for the ~~six~~nine months ended ~~June~~September 30, 2021. This decrease was due to an increase in reserves for excess inventory as result of a forecasted decline in demand and a less favorable product mix.

Research and development expenses increased ~~11%~~3% to ~~$5.7~~$8.1 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$5.1~~$7.9 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to higher staffing costs. Sales and marketing expenses increased ~~18%~~1% to ~~$8.5~~$12.3 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$7.2~~$12.1 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to higher staffing costs related to increased head count, increased consulting expense associated with business strategy planning, and an increase in travel costs as COVID-19 restrictions are lifted. These increases in expenses were partially offset by lower amortization expense associated with an intangible asset that was fully amortized at the end of ~~2021.~~2021, lower commission, and a decrease in expense related to the cancellation of a marketing loyalty program. General and administrative expenses increased ~~58%~~53% to $18.6 million for the nine months ended September 30, 2022 from $12.1 million for the ~~six~~nine months ended ~~June 30, 2022 from $7.6 million for the six months ended June~~September 30, 2021 due to increased legal fees, higher non-cash stock compensation expense and increased staffing costs.

Operating expenses for the Molecular Solutions segment also includes an impairment ~~charge~~charges of ~~$2.0~~$8.6 million for the ~~six~~nine months ended ~~June~~September 30, 2022 associated with ~~two~~several idle manufacturing lines for which there are no projected cash ~~flow~~flows and minimal resale or salvage value.

All of the above contributed to the Molecular Solutions segment’s operating loss of ~~$5.7~~$16.1 million for the ~~six~~nine months ended ~~June~~September 30, 2022, which included the non-cash impairment ~~charge~~charges of ~~$2.0~~$8.6 million, ~~$3.8~~$5.6 million for depreciation and amortization and ~~$924,000~~$1.6 million for stock-based compensation.

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established against our total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the ~~six~~nine months ended ~~June~~September 30, 2022, we recorded U.S. state tax expense of ~~$400,000~~$379,000 compared to ~~$115,000~~$13,000 of state income tax expense for the ~~six~~nine months ended ~~June~~September 30, 2021. Additionally, in the first ~~half~~nine months of 2022, we recorded approximately $1.7 million of withholding taxes due to the Canada Revenue Agency associated with our repatriation of $65.0 million of cash from Canada to the United States. For the ~~six~~nine months ended ~~June~~September 30, 2022, we recorded a foreign tax ~~expense~~benefit of ~~$665,000~~$438,000 compared to foreign tax expense of ~~$10.0~~$12.2 million for the ~~six~~nine months ended ~~June~~September 30, 2021. This overall decrease in foreign tax expense is largely a result of the decrease in income before taxes generated by our Canadian subsidiary.

Liquidity and Capital Resources


	June 30,		December 31,		September 30,		December 31,
	2022		2021		2022		2021
	(In thousands)				(In thousands)
Cash and cash equivalents	$	66,159	$	116,762	$	75,205	$	116,762
Available for sale securities		29,625		53,288		26,432		53,288
Working capital		201,820		220,367		208,035		220,367

Our cash and cash equivalents and available-for-sale securities decreased to ~~$95.8~~$101.6 million at ~~June~~September 30, 2022 from $170.1 million at December 31, 2021. Our working capital decreased to ~~$201.8~~$208.0 million at ~~June~~September 30, 2022 from $220.4 million at December 31, 2021.

During the ~~six~~nine months ended ~~June~~September 30, 2022, net cash used in operating activities was ~~$45.5~~$29.2 million. Our net loss of ~~$38.8~~$33.5 million included non-cash charges of ~~$10.5~~$17.1 million associated with impairment charges taken ~~against~~for idle manufacturing lines and goodwill, depreciation and amortization expense of ~~$7.5~~$11.4 million, stock-based compensation expense of ~~$6.8~~$9.1 million, an inventory reserve of ~~$2.0 million,~~$977,000, an increase in our reserve for uncollectible accounts of $974,000 and other non-cash expense of ~~$1.2~~$1.3 million. Cash used to fund our working capital accounts included an increase in inventory of ~~$20.4~~$27.6 million to meet

anticipated demand to support COVID-19 testing program, an increase in accounts receivable of ~~$18.6~~$19.2 million largely associated with product shipped to the U.S. government, a ~~$4.1~~$6.0 million increase in prepaid expenses and other assets associated with tax installments made to the Canadian Revenue ~~Agency and a $2.9 million decrease in accrued expenses and other liabilities largely due to payment of our 2021 bonuses and severance payments to our former CEO.~~Agency. Offsetting these uses of cash was ~~a $11.9~~$16.2 million increase in accounts payable due to the timing of invoices received and payments made.

Net cash used in investing activities was ~~$2.3~~$4.5 million for the ~~six~~nine months ended ~~June~~September 30, 2022, which reflects proceeds from the maturities and redemptions of investments of ~~$23.0~~$47.4 million. This was offset by ~~$25.4~~$28.1 million to acquire property and equipment largely to increase our manufacturing ~~capacity.~~capacity and $22.9 million of investment purchases.

Net cash used in financing activities was ~~$2.5~~$3.0 million for the ~~six~~nine months ended ~~June~~September 30, 2022, which is largely comprised of $2.0 million used for the repurchase of common stock to satisfy withholding taxes related to the vesting of restricted shares awarded to our employees.

We expect current balances of cash and cash equivalents and available-for-sale securities to be sufficient to fund our current operating and capital needs as well as those arising over the next twelve months. Our cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the timing of reimbursement under our $109 million DOD contract, the scope and timing of future strategic acquisitions, the progress of our research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the timing and cost of future stock purchases, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the current economic environment and other factors. In addition, ~~$74.7~~$75.2 million or ~~78%~~74% of our ~~$95.8~~$101.6 million in cash, cash equivalents and available-for-sale securities belongs to our Canadian subsidiary. In the first quarter of 2022, we repatriated $65.0 million of cash from Canada into the United States and incurred approximately $1.7 million of Canadian withholding tax. Further repatriation of cash from Canada into the United States could have additional adverse tax consequences. It is our intention going forward to continue to permanently reinvest the historical undistributed earnings of our foreign subsidiaries.

A summary of our obligations to make future payments under contracts existing at December 31, 2021 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2021. As of ~~June~~September 30, 2022, there were no significant changes to this information.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these

financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to the bad debts, customer sales returns, inventories, intangible assets, income taxes, revenue recognition, performance-based compensation, contingencies and litigation. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

A more detailed review of our critical accounting policies is contained in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. Except as presented below, no material changes have been made to such critical accounting policies during the ~~six~~nine months ended ~~June~~September 30, 2022.

Goodwill

Goodwill is not amortized, but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment and Ifif it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. An impairment charge is recognized in the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The process of evaluating the potential impairment of goodwill is highly subjective and requires significant judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.

As of ~~June~~September 30, 2022, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. Sales denominated in foreign currencies comprised ~~3.5%~~2.7% of our total revenues for the ~~six~~nine months ended ~~June~~September 30, 2022. We do have foreign currency exchange risk related to our operating subsidiaries in Canada and in Belgium. The principal foreign currencies in which we conduct business are the Canadian dollar and the Euro. Fluctuations in the exchange rate between the U.S. dollar and these foreign currencies could affect year-to-year comparability of operating results and cash flows. Our foreign subsidiaries had net assets, subject to translation, of ~~$130.9~~$117.2 million in U.S. Dollars, which are included in the Company’s consolidated balance sheet as of ~~June~~September 30, 2022. A 10% unfavorable change in the Canadian-to-U.S. dollar and Euro-to-U.S. dollar exchange rates would have decreased our comprehensive income by approximately ~~$13.1~~$11.7 million in the ~~six~~nine months ended ~~June~~September 30, 2022.

Item 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and ~~Interim~~ Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of ~~June~~September 30, 2022. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures were effective as of ~~June~~September 30, 2022 to provide reasonable assurance that material information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 was accumulated and communicated to the Company’s management, including the Chief Executive Officer and ~~Interim~~ Chief Financial Officer, to allow timely decisions regarding required disclosure and was recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

(b) Changes in Internal Control Over Financial Reporting. There was no change in the Company’s internal control over financial reporting that occurred during the three months ended ~~June~~September 30, 2022 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on our future financial position or results of operations.

Spectrum Patent Litigation

In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the ~~litigation.~~litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office. DNAG filed a motion to dismiss Spectrum’s counterclaims in October 2021, which was denied by the Court on March 30, 2022. ~~On April 8, 2022, the Court assigned a new judge to preside over the matter, which vacated all dates~~Fact discovery is ongoing. The final pretrial conference is set for ~~the trial. We await new dates to be set by the Court.~~September 7, 2023

Item 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed in Item 1A, entitled “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2021, other than as set forth below.

Customer Concentration Creates Risk for Our Business.

One non-commercial customer accounted for ~~56%~~69% and ~~39%~~53% of net consolidated revenues for the three and ~~six~~nine months ended ~~June~~September 30, 2022. We

expect that sales to the large non-commercial customer will continue to be a significant contributor to our net consolidated revenue. Certain parts of our business may continue to have a high customer concentration and depend disproportionately on a few large customers. To the extent that such a large customers fail to meet their purchase commitments, change their ordering patterns or business strategies, or otherwise reduce their purchases or stop purchasing our products, or if we experience difficulty in meeting the high demand by these larger customers for our products, our revenues and results of operations could be adversely affected.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Period

Total number of
shares purchased

Average price
paid per Share

Total number of
shares purchased
as part of publicly
announced plans
or programs

Maximum number (or
approximate dollar value)
of shares that may yet be
repurchased under the plans
or programs (1, 2)

April 1, 2022 - April 30, 2022

107,316

(3)

$
7.08

—

11,984,720

May 1, 2022 - May 31, 2022

21,979

(3)

5.17

—

11,984,720

June 1, 2022 - June 30, 2022

12,311

3.83

—

11,984,720

141,606

—


Period	Total number of shares purchased			Average price paid per Share		Total number of shares purchased as part of publicly announced plans or programs		Maximum number (or approximate dollar value) of shares that may yet be repurchased under the plans or programs (1, 2)
July 1, 2022 - July 31, 2022		19,470	(3)	$	2.78		—		11,984,720
August 1, 2022 - August 31, 2022		—			—		—		11,984,720
September 1, 2022 - September 30, 2022		—			—		—		11,984,720
		19,470					—

(1)

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25.0 million of outstanding shares. This share repurchase program may be discontinued at any time.

(2)

This column represents the amount that remains available under the $25.0 million repurchase plan, as of the period indicated. We have made no commitment to purchase any shares under this plan.

(3)

Pursuant to the OraSure Technologies, Inc. Stock Award Plan, and in connection with the vesting of restricted and performance shares, these shares were retired to satisfy minimum tax withholdings.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None

Item 4. MINE SAFETY DISCLOSURES

Not applicable

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS



Exhibit Number		Exhibit

10.1**		~~Amended and Restated~~Employment Agreement dated August 8, 2022, between OraSure Technologies, Inc. ~~2000 Stock Award Plan~~and Kenneth J. McGrath is incorporated by reference to Exhibit 10.1 to the Company's Current Report on ~~Form~~form 8-K filed ~~May 18, 2022.~~

10.2**		Employment Agreement dated as of May 20, 2022, between OraSure Technologies, Inc. and Carrie Eglinton-Manner is incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed May 26,August 12, 2022.

31.1*		Certification of Carrie Eglinton-Manner required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2*		Certification of ~~Scott Gleason~~Kenneth J. McGrath required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1*+		Certification of Carrie Eglinton-Manner required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*+		Certification of ~~Scott Gleason a~~Kenneth J. McGrath required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document – the Instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

Exhibit 104		Cover Page from the Company’s Quarterly Report on Form 10-Q for the Quarter Ended ~~June~~September 30, 2021 has been formatted in Inline XBRL

*Filed herewith

** Management contract or compensatory plan or arrangement.

+This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


	ORASURE TECHNOLOGIES, INC.

		/s/ ~~Scott Gleason~~Kenneth J. McGrath
Date: ~~August 9,~~November 8, 2022		~~Scott Gleason~~Kenneth J. McGrath
		~~Senior Vice President, Investor Relations and Corporate Communications~~Chief Financial Officer
		(Principal Financial Officer)

		/s/Michele M. ~~Miller~~Anthony
Date: ~~August 9,~~November 8, 2022		Michele M. ~~Miller~~Anthony
		Senior Vice President, Controller and Chief Accounting Officer
		(Principal Accounting Officer)


	Finance			Operating
2022 (excluding the six months ended June 30, 2022)	$	710		$	1,496
2023		1,283			1,879
2024		740			2,969
2025		19			2,619
2026		11			2,422
Thereafter		—			9,021
Total minimum lease payments		2,763			20,406
Less: imputed interest		(136	)		(3,374	)
Present value of lease liabilities	$	2,627		$	17,032